Hartung H-P et al. Mitoxantrone in progressive multiple sclerosis: a placebo controlled, double blind randomised multicentre trial. The Lancet 2002; 360: 2018-2025.
194 patients with worsening RRMS or SPMS were given MTX or placebo q 3 months for 24 months (5 mg/meter squared). at end, the treated group had a benefit in five clinical primary outcome measures: change in EDSS, change in ambulation index, adjusted total number of treated relapses, time to first treated relapse, and change in standard neurological status.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment